On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...

Findings showed datopotamab deruxtecan reduced the risk of disease progression or death by 37% compared with chemotherapy.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).